The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Effect of maintenance bevacizumab (Bev) plus pemetrexed (Pem) after first-line cisplatin/Pem/Bev in advanced nonsquamous non-small cell lung cancer (nsNSCLC) on overall survival (OS) of patients (pts) on the AVAPERL (MO22089) phase III randomized trial.
Achim Rittmeyer
No relevant relationships to disclose
Arnaud Scherpereel
Honoraria - Roche
Research Funding - Roche
Vera A. Gorbunova
No relevant relationships to disclose
Radj Gervais
No relevant relationships to disclose
Anders Vikström
Honoraria - Lilly; Roche
Research Funding - Roche
Christos Chouaid
No relevant relationships to disclose
Antonio Chella
No relevant relationships to disclose
Joo-Hang Kim
No relevant relationships to disclose
Myung-Ju Ahn
No relevant relationships to disclose
Martin Reck
Consultant or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo; Lilly; Pfizer; Roche
Honoraria - AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo; Lilly; Pfizer; Roche
Antonio Pazzola
No relevant relationships to disclose
Heung Tae Kim
No relevant relationships to disclose
Joachim Aerts
No relevant relationships to disclose
Harry J.M. Groen
Consultant or Advisory Role - Lilly; Pfizer; Roche
Research Funding - Lilly; Roche
Claire Morando
No relevant relationships to disclose
Anderson Loundou
No relevant relationships to disclose
Fabrice Barlesi
Consultant or Advisory Role - Lilly; Roche
Research Funding - Roche